ProShare Advisors
VYNE icon

ProShare Advisors’s VYNE Therapeutics VYNE Stock Holding History

ProShare Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-611
Closed -$15K – 2352
2021
Q3 		$15K Buy
+611
New +$23.7K ﹤0.01% 2000
2021
Q2 		– Sell
-933
Closed -$115K – 2409
2021
Q1 		$115K Buy
933
+126
+16% +$18.3K ﹤0.01% 2146
2020
Q4 		$92K Buy
807
+560
+227% +$70.4K ﹤0.01% 2003
2020
Q3 		$30K Buy
247
+46
+23% +$5.37K ﹤0.01% 1616
2020
Q2 		$25K Buy
+201
New +$27.2K ﹤0.01% 1655

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ProShare Advisors's VYNE Position: Q4 2021 in Review

ProShare Advisors sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 611 shares — an estimated $15K sold.

ProShare Advisors first reported a position in VYNE in Q2 2020 and held it in 5 quarters. The position peaked at $115K in Q1 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

  • ProShare Advisors reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
  • ProShare Advisors sold 611 VYNE Therapeutics shares in Q4 2021, an estimated $15K.
  • ProShare Advisors first reported a position in VYNE Therapeutics in Q2 2020 and held it in 5 quarters.
  • ProShare Advisors's VYNE Therapeutics position peaked at $115K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.